Methyl salicylate (methyl 2-hydroxybenzoate, CAS 119-36-8) is the ester of salicylic acid responsible for the characteristic wintergreen scent of many Chinese medicated oils, Southeast Asian balms, and Western topical analgesics. Extracted historically from wintergreen (Gaultheria procumbens) and sweet birch bark, it is now produced synthetically at scale. Among the classic medicated-oil ingredients — camphor, menthol, eucalyptus oil — methyl salicylate is unique because it delivers both a sensory counter-irritant effect and a genuine biochemical anti-inflammatory action once hydrolysed in the skin. That dual mechanism makes it clinically effective. It also makes it the most toxicologically consequential ingredient in the typical medicated-oil formulation.
This article explains how methyl salicylate acts at the molecular level, where it appears in commercial products, what the real safety boundaries are, and how regulators in Hong Kong and the United States control its use.
Methyl salicylate exerts its analgesic and anti-inflammatory effects through two distinct but complementary pathways.
After penetrating the stratum corneum, methyl salicylate is hydrolysed by carboxylesterases in the epidermis, dermis, and systemic circulation to yield salicylic acid — the same active metabolite produced by aspirin. Salicylic acid is a non-selective inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). By blocking these enzymes, it reduces the local synthesis of prostaglandins — particularly PGE₂ and PGI₂ — that sensitise peripheral nociceptors and drive the cardinal signs of inflammation: redness, swelling, heat, and pain.
This mechanism is not merely theoretical. Pharmacokinetic studies confirm that topical application of methyl salicylate at concentrations found in commercial products (10–30%) produces measurable plasma salicylate levels. Applied to a single joint area, these levels remain sub-therapeutic systemically but are sufficient for local anti-inflammatory action in the underlying muscle and connective tissue.
The immediate warming sensation produced by methyl salicylate on the skin is mediated primarily through transient receptor potential vanilloid 1 (TRPV1) channels. TRPV1 is a polymodal nociceptor expressed on C-fibre and Aδ sensory neurons; it is the same receptor activated by capsaicin and by noxious heat above 43°C. Methyl salicylate acts as a moderate TRPV1 agonist, producing a sensation of warmth without tissue damage.
This TRPV1-driven warmth triggers the gate-control mechanism of counter-irritation: afferent signals from the stimulated skin surface compete with and partially inhibit deeper pain signals ascending through the dorsal horn of the spinal cord. The result is a rapid, perceptible reduction in musculoskeletal pain that begins within minutes of application — well before the slower COX-inhibition pathway takes effect.
Additionally, methyl salicylate causes local vasodilation via axon-reflex mechanisms and nitric oxide release. Increased blood flow to the treated area accelerates clearance of inflammatory mediators and contributes to the subjective feeling of relief.
The two pathways are temporally complementary: TRPV1-mediated counter-irritation provides fast-onset relief (2–5 minutes), while COX inhibition builds over 30–60 minutes and sustains the anti-inflammatory effect for several hours.
Methyl salicylate appears across a wide spectrum of medicated oils, balms, and patches. The concentration determines both efficacy and risk profile.
| Product | Methyl salicylate (%) | Format | Primary market |
|---|---|---|---|
| Tiger Balm White | ~15% | Ointment | Global / Southeast Asia |
| Tiger Balm Red | ~10% | Ointment | Global / Southeast Asia |
| Salonpas Pain Relief Patch | ~6–10% | Adhesive patch | Japan / US / Asia |
| Deep Heat Rub | ~12% | Cream | UK / Australia / HK |
| Bengay Ultra Strength | ~30% | Cream | US |
| Kwan Loong Oil (均隆驅風油) | ~15% | Liquid oil | Malaysia / HK |
| White Flower Oil (白花油) | ~40% | Liquid oil | HK / Southeast Asia |
In TCM medicated-oil formulations, methyl salicylate is rarely used alone. It is typically combined with menthol (cooling, TRPM8-mediated), camphor (warming, TRPV3-mediated), and eucalyptus oil (1,8-cineole). The sensory interplay between these ingredients — cool and warm channels activated simultaneously — is a defining characteristic of the traditional balm experience and has a pharmacological basis in multi-receptor modulation of nociceptive signalling.
Patch formulations such as Salonpas use lower concentrations because occlusion by the adhesive backing increases skin absorption, effectively amplifying the delivered dose.
Methyl salicylate is dense (1.17 g/mL) and one millilitre contains approximately 1.4 g of salicylate equivalent. A single teaspoon (5 mL) of pure oil of wintergreen delivers roughly 7 g of salicylate — equivalent to over 20 standard aspirin tablets. In children, the estimated minimum lethal oral dose is as low as 100 mg/kg body weight, meaning less than one teaspoon can be fatal for a toddler.
Methyl salicylate is highly lipophilic and penetrates skin readily. Absorption is significantly increased by heat, occlusion (bandaging or clothing), broken skin, and exercise-induced vasodilation. Under these conditions, topical application to large body surface areas can produce plasma salicylate levels approaching therapeutic oral doses — a reality demonstrated fatally in the 2007 Arielle Newman case, where an adolescent athlete died from chronic excessive topical use.
Children under 12 should not use methyl salicylate products. Three factors compound risk in pediatric populations: higher body-surface-area-to-mass ratio (increasing relative dose), immature hepatic metabolism (slower salicylate clearance), and the theoretical risk of Reye’s syndrome when salicylates are combined with viral illness. For infants, even small topical applications can generate disproportionately high plasma levels. Pure oil of wintergreen must be stored with the same precautions as a pharmaceutical poison in any household with young children.
In Hong Kong, topical methyl salicylate products are regulated under the Pharmacy and Poisons Ordinance (Cap. 138) and the Chinese Medicine Ordinance (Cap. 549) depending on whether they are classified as pharmaceutical products or proprietary Chinese medicines (pCm). Products registered as pCm with the Chinese Medicine Council of Hong Kong must declare methyl salicylate concentration and carry safety warnings. There is no single statutory concentration cap for methyl salicylate in topical products, but the Department of Health has issued safety communications recommending adherence to international limits and appropriate labelling for products exceeding 10%.
The US FDA regulates methyl salicylate in OTC topical analgesics under the OTC Monograph system (21 CFR 348). The permitted concentration range for methyl salicylate as a single active ingredient is 10–60% in ointments and liniments, and 10–15% in plasters/patches. Products must carry warnings against use in children under 12, use on damaged skin, and concurrent use with heating pads or other salicylate products. The Poison Prevention Packaging Act requires child-resistant closures for liquid products containing more than 5% methyl salicylate.
Following the 2007 Newman fatality, the FDA issued additional guidance emphasising the risk of topical salicylate toxicity from excessive application, product stacking, and use during vigorous exercise.
Methyl salicylate remains one of the most pharmacologically effective ingredients in the medicated-oil tradition — a genuine dual-mechanism analgesic with over a century of clinical use. Its efficacy is matched by a toxicity profile that demands respect. Correct use on small areas of intact skin, away from heat, in adults, delivers reliable pain relief. Misuse — in children, over large areas, under occlusion, or in combination with other salicylates — can be fatal.
This article is part of the Medicated Oil Knowledge Hub, a free educational reference on traditional Chinese and Southeast Asian herbal medicated oils. Information here is for education, not medical advice.